News & Updates
Filter by Specialty:
Antiseizure drug yields durable seizure frequency reduction, lowers concomitant medication burden
In the treatment of adults with uncontrolled focal seizures, the long-term, open-label use of cenobamate appears to produce high rates of sustained 100-percent and ≥90-percent seizure reduction, with parallel decreases in concomitant antiseizure medication (ASM) doses, according to two separate post hoc analyses of a phase III C021 trial.
Antiseizure drug yields durable seizure frequency reduction, lowers concomitant medication burden
12 Nov 2021
Belimumab after rituximab reduces risk for severe flare in SLE
Treatment with belimumab following rituximab significantly lowers serum IgG anti-dsDNA antibody levels and the risk for severe flare in patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, reveals a study.
Belimumab after rituximab reduces risk for severe flare in SLE
10 Nov 2021
A3 adenosine receptor agonist safe, effective for treating NAFLD
Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.
